Liminal BioSciences: Jumps as FDA to review license application for genetic disorder drug

Liminal BioSciences

21/09/2020 14:28

** Canadian drugmaker's  LMNL.TO  U.S. shares  LMNL.O  rise
12.8% to $13.4 premarket
    ** Says the FDA acknowledged receipt of resubmission of the
Biologic License Application for Ryplazim, for the treatment of
plasminogen deficiency, by its U.S. subsidiary Prometic
Biotherapeutics Inc  urn:newsml:reuters.com:*:nCNWB3qkJa
    ** Deficiency is a genetic disorder associated with
inflammed growths on the mucous membranes 
    ** FDA has provided a Prescription Drug User Fee Act target
action date of March 5, 2021
    ** LMNL sees potential approval and commercial launch of
Ryplazim in U.S. in 2021 
    ** Up to Friday's close, stock rose ~42% YTD
    

 (Reporting by Shivani Kumaresan in Bengaluru)
 ((Shivani.Kumaresan@thomsonreuters.com ; +1 646 223 8780;))